Press Release Acuity Bio CEO interviewed by StockTube Dr. John Jay Schwartz interviewed in regards to Acuity Bio’s proprietary ABC103 Product.
Newton, Massachusetts (August 4, 2018) – Acuity Bio Inc., a developer of novel drug delivery, combination products, announced today that its CEO John Jay Schwartz has been interviewed by Stocktube in regards to Acuity Bio’s proprietary ABC 103 product. The full interview may be viewed at the following URL: https://www.youtube.com/embed/WLwo-53S1U8
About Acuity Bio Acuity Bio has developed a platform technology for localized, sustained, safe drug-delivery to be used in the prevention of post-surgical lung cancer recurrence. ABC 103 combines approved/ cleared surgical staple line buttress, drug eluting polymers and a chemotherapeutic drug, paclitaxel). ABC103 has been granted US FDA orphan drug designation for this indication. Phase I clinical testing of ABC103 is scheduled to commence late 2019. Other applications for ABC drug-delivery platform in are under development. For more information visit www.acuitybio.com.
Acuity Bio’s Forward-Looking Statement Disclaimer Various statements in this release concerning Acuity Bio’s future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. In addition, any forward-looking statements represent Acuity Bio’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Acuity Bio does not assume any obligation to update any forward-looking statements unless required by law.
Acuity Bio Contact: John “Jay” Schwartz, President & CEO firstname.lastname@example.org